恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

午间休市 02-05 12:05:00

68.350

+1.600

+2.40%

最高69.250	最低66.000	成交量116.53万
今开66.700	昨收66.750	日振幅4.87%
总市值4,536亿	流通市值176.34亿	总股本66.37亿
成交额7,959万	换手率0.45%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":68.35,"timestamp":1770264300002,"preClose":66.75,"halted":0,"volume":1165310,"delay":0,"changeRate":0.023970037453183435,"floatShares":258000000,"shares":6637000000,"eps":1.1244465960287653,"marketStatus":"午间休市","change":1.6,"latestTime":"02-05 12:05:00","open":66.7,"high":69.25,"low":66,"amount":79585299,"amplitude":0.048689,"askPrice":68.35,"askSize":8000,"bidPrice":68.25,"bidSize":1200,"shortable":3,"etf":0,"ttmEps":1.3045919362853415,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770267600000},"marketStatusCode":3,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":66.75,"openAndCloseTimeList":[[1770255000000,1770264000000],[1770267600000,1770278400000]],"volumeRatio":0.5844,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":57.96,"timestamp":1770262201000,"preClose":57.6,"halted":0,"volume":31236800,"delay":0,"premium":"+4.87"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"2609834341","title":"港股恒瑞医药涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609834341","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609834341?lang=zh_cn&edition=full","pubTime":"2026-02-05 11:30","pubTimestamp":1770262239,"startTime":"0","endTime":"0","summary":"每经AI快讯，恒瑞医药(01276.HK)涨超3%，截至发稿，涨3%，报68.75港元，成交额7126.63万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602053642588111.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602053642588111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","LU0359202008.SGD","LU1064131003.USD","LU1997244956.HKD","BK4585","LU0359201885.HKD","BK0196","LU0359201612.USD","LU2289578879.USD","LU2580892789.USD","VXUS","BK0188","LU2488822045.USD","LU1146622755.USD","LU1023057109.AUD","LU2580892862.HKD","BK0183","LU0405327494.USD","VT","BK0028","LU2148510915.USD","LU1328615791.USD","LU1580142542.USD","LU2495084118.USD","LU2097828805.USD","BK0012","LU1997245177.USD","LU2097828557.USD","LU2328871848.SGD","LU0405327148.USD","LU1655091616.SGD","LU2543165471.USD","LU2097828474.EUR","600276","LU1064130708.USD","LU2097828631.EUR","LU1781817850.SGD","LU1820825898.SGD","01276","BK0239","LU1997245094.SGD","LU1255011170.USD","LU1969619763.USD","LU2097828714.EUR","BK1191","BK4588"],"gpt_icon":0},{"id":"1166243807","title":"江苏恒瑞医药（600276）回购16.5万股A股，总额约931.7万元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1166243807","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166243807?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:53","pubTimestamp":1770195236,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司于2026年2月4日公告，基于A股员工持股计划回购股份16.5万股，约占公司现有已发行股本的0.0026%。回购价格区间为每股人民币56.25元至57.09元，合计支付约人民币931.7万元。\n本次回购完成后，公司已发行股本变动为6,373,743,624股，库存股数量增至5,258,650股。公司同时确认，相关股份购回及后续安排已遵守上市规则及相关法律法规的要求。\n公告由联席公司秘书刘笑含签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"gpt_icon":0},{"id":"2608351186","title":"恒瑞医药(01276)2月4日斥资931.7万元回购16.5万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608351186","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608351186?lang=zh_cn&edition=full","pubTime":"2026-02-04 16:46","pubTimestamp":1770194772,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，于2026年2月4日，该公司斥资931.7万元回购16.5万股A股。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0060","LU2097828557.USD","399300","LU0405327148.USD","LU2097828714.EUR","LU2097828631.EUR","LU1328615791.USD","LU2580892789.USD","LU1781817850.SGD","LU1580142542.USD","BK0239","LU2495084118.USD","LU2543165471.USD","LU2488822045.USD","BK0012","LU0359201885.HKD","LU1146622755.USD","LU1023057109.AUD","LU2148510915.USD","LU1997244956.HKD","LU2580892862.HKD","LU1997245094.SGD","LU2097828474.EUR","01276","LU2328871848.SGD","LU0359202008.SGD","LU1997245177.USD","600276","LU1655091616.SGD","LU2097828805.USD","BK0028","BK0183","LU1969619763.USD","LU1064130708.USD","LU0405327494.USD","BK0188","159982","BK0196","BK1191","LU1820825898.SGD","LU1064131003.USD","LU2289578879.USD","LU0359201612.USD","LU1255011170.USD"],"gpt_icon":0},{"id":"2608335923","title":"恒瑞医药：HER2 ADC拿下第10项突破治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2608335923","media":"医药笔记","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608335923?lang=zh_cn&edition=full","pubTime":"2026-02-04 09:03","pubTimestamp":1770167012,"startTime":"0","endTime":"0","summary":"▎Armstrong2026年2月3日，恒瑞医药HER2 ADC新药SHR-A1811一线治疗HER2激活突变NSCLC拟纳入突破治疗药物程序。总结恒瑞医药将ADC作为其布局重点，并积极开发下一代的新毒素ADC，以及第三代的双毒素ADC。除此之外，恒瑞医药扩展布局到DAC、APC、AOC等领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204093203a6d07e08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204093203a6d07e08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","LU0359202008.SGD","BK1191","LU0359201612.USD","LU0359201885.HKD","LU2543165471.USD","01276"],"gpt_icon":0},{"id":"2608872130","title":"恒瑞医药：公司日常经营管理和业务状况正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2608872130","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608872130?lang=zh_cn&edition=full","pubTime":"2026-02-03 22:07","pubTimestamp":1770127673,"startTime":"0","endTime":"0","summary":"证券日报网讯2月3日，恒瑞医药在互动平台回答投资者提问时表示，公司日常经营管理和业务状况正常，不存在按规定应披露而未披露的重大信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602033640420282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","LU1997245094.SGD","LU1969619763.USD","LU2289578879.USD","LU2148510915.USD","LU2580892789.USD","BK1191","LU0359201612.USD","LU2580892862.HKD","LU2097828805.USD","LU1580142542.USD","LU1328615791.USD","LU2097828474.EUR","LU1997244956.HKD","LU1997245177.USD","LU2097828557.USD","BK0028","LU1146622755.USD","BK0012","BK0188","LU0359202008.SGD","LU0359201885.HKD","LU2097828714.EUR","LU1064130708.USD","LU0405327494.USD","LU0405327148.USD","LU2488822045.USD","LU1655091616.SGD","LU1064131003.USD","BK0196","LU1781817850.SGD","LU2097828631.EUR","01276","600276","BK0183","LU2328871848.SGD","LU1023057109.AUD","LU1255011170.USD","LU2543165471.USD","BK0060","LU1820825898.SGD","LU2495084118.USD"],"gpt_icon":0},{"id":"2608287131","title":"恒瑞医药：重新提交注射用卡瑞利珠单抗联合方案获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2608287131","media":"财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608287131?lang=zh_cn&edition=full","pubTime":"2026-02-03 20:46","pubTimestamp":1770122760,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药发布公告称，公司收到美国食品药品监督管理局的《确认函》，公司重新提交的注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片用于不可切除或转移性肝细胞癌患者的一线治疗的生物制品许可申请获得FDA受理。国内也有多款同类产品获批上市。经查询EvaluatePharma数据库，2024年抗PD-1抗体全球销售额合计约为415.46亿美元。截至目前，注射用卡瑞利珠单抗相关项目累计研发投入约为319,740万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-03/doc-inhkpzpf7190703.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-02-03/doc-inhkpzpf7190703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2328871848.SGD","LU2543165471.USD","LU0359202008.SGD","LU0359201612.USD","LU2580892789.USD","BK1191","LU1781817850.SGD","LU2495084118.USD","LU1064130708.USD","LU1328615791.USD","LU2488822045.USD","LU0405327148.USD","LU1655091616.SGD","LU2097828557.USD","LU2097828631.EUR","BK0239","LU2097828474.EUR","LU1023057109.AUD","BK0183","LU1820825898.SGD","LU2097828714.EUR","LU1255011170.USD","LU1997245177.USD","LU1064131003.USD","BK0028","BK0188","LU0405327494.USD","BK0060","01276","LU2097828805.USD","LU1997244956.HKD","LU1997245094.SGD","LU2289578879.USD","BK0012","LU0359201885.HKD","600276","LU2580892862.HKD","LU1146622755.USD","LU1580142542.USD","LU2148510915.USD","LU1969619763.USD","BK0196"],"gpt_icon":0},{"id":"2608842390","title":"恒瑞医药董事会换届延期 现任班子继续履职","url":"https://stock-news.laohu8.com/highlight/detail?id=2608842390","media":"中访网数据","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608842390?lang=zh_cn&edition=full","pubTime":"2026-02-03 00:30","pubTimestamp":1770049800,"startTime":"0","endTime":"0","summary":"中访网数据江苏恒瑞医药股份有限公司（股票代码：600276）于2月2日发布公告，宣布其第九届董事会任期已于2026年2月1日届满。鉴于新一届董事会换届筹备工作仍在进行中，为确保公司治理的连续性与稳定，公司决定将董事会换届选举工作适当延期。在此期间，公司第九届董事会全体董事、各专门委员会成员及高级管理人员将继续依照法律法规及《公司章程》的规定，履行相应职责。公司表示，此次董事会延期换届不会对公司的正常运营产生影响，目前正积极推进换届工作，并将及时履行后续的信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203003121a474050c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203003121a474050c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","LU1023057109.AUD","01276","BK1191","LU2543165471.USD","LU0359201612.USD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2608854966","title":"恒瑞医药回购979万股 金额6.46亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608854966","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608854966?lang=zh_cn&edition=full","pubTime":"2026-02-02 17:00","pubTimestamp":1770022804,"startTime":"0","endTime":"0","summary":"2月2日，恒瑞医药（600276/01276）发布公告，截至2026年1月31日，公司已回购979万股，占总股本的0.15%，回购资金总额为6.46亿元，回购价格区间为56.1元/股至70元/股。2025年前三季度，恒瑞医药实现收入231.88亿元，归母净利润57.51亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638729383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","LU2097828631.EUR","LU1580142542.USD","LU1997245094.SGD","LU2328871848.SGD","LU1146622755.USD","LU0359201885.HKD","LU1328615791.USD","LU1655091616.SGD","LU0359202008.SGD","BK0239","LU2097828714.EUR","LU2097828474.EUR","BK0183","01276","LU1997244956.HKD","BK0028","LU2148510915.USD","BK0060","LU2543165471.USD","LU2580892789.USD","LU2289578879.USD","BK0012","LU0405327494.USD","BK0196","LU1997245177.USD","LU1820825898.SGD","LU2097828805.USD","600276","LU1064130708.USD","LU1023057109.AUD","LU2488822045.USD","LU2580892862.HKD","LU2495084118.USD","LU1781817850.SGD","LU0359201612.USD","LU1064131003.USD","LU0405327148.USD","LU1969619763.USD","LU1255011170.USD","BK0188","LU2097828557.USD"],"gpt_icon":0},{"id":"2608859435","title":"恒瑞医药(600276.SH)重新提交注射用卡瑞利珠单抗的生物制品许可申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2608859435","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608859435?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:35","pubTimestamp":1770021352,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)公告，公司收到美国食品药品监督管理局(简称“FDA”)的《确认函》，公司重新提交的注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片用于不可切除或转移性肝细胞癌患者的一线治疗的生物制品许可申请(简称“BLA”)获得FDA受理。根据《处方药用户付费法案(PDUFA)》，FDA对注射用卡瑞利珠单抗的目标审评日期为2026年7月23日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400545.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1781817850.SGD","LU2097828714.EUR","LU1997245094.SGD","LU2580892789.USD","BK0239","LU2097828557.USD","LU0359201612.USD","LU1023057109.AUD","BK1191","01276","LU1997245177.USD","LU0359202008.SGD","LU2097828631.EUR","LU1146622755.USD","LU2495084118.USD","LU1255011170.USD","LU2097828474.EUR","LU2097828805.USD","LU1064130708.USD","LU1820825898.SGD","LU2148510915.USD","LU1997244956.HKD","BK0183","LU1580142542.USD","LU0359201885.HKD","LU1328615791.USD","600276","BK0196","LU2488822045.USD","LU1655091616.SGD","LU1969619763.USD","LU2328871848.SGD","LU0405327494.USD","BK0028","BK0012","BK0060","LU2543165471.USD","LU2580892862.HKD","LU2289578879.USD","LU1064131003.USD","LU0405327148.USD","BK0188"],"gpt_icon":0},{"id":"2608842315","title":"每日卖空追踪 | 恒瑞医药 02月02日卖空量成交28.84万股，卖空比例为6.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608842315","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608842315?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:30","pubTimestamp":1770021020,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间02月02日，跌2.12%，卖空量成交28.84万股，较上一交易日减少77.1%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202163313a6c9825c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202163313a6c9825c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","BK1191","LU0359201612.USD","LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD","01276"],"gpt_icon":0},{"id":"2607079305","title":"专访恒瑞医药贺峰博士 | 不止于一款新药：从艾泽利®看恒瑞医药的平台化创新生态与管线蓝图","url":"https://stock-news.laohu8.com/highlight/detail?id=2607079305","media":"中国医药创新促...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607079305?lang=zh_cn&edition=full","pubTime":"2026-01-31 10:30","pubTimestamp":1769826642,"startTime":"0","endTime":"0","summary":"本文转载自药时代作者：药时代团队菜一碟近期，中国创新药研发迎来又一里程碑时刻：恒瑞医药宣布，公司自主研发的1类创新药瑞拉芙普α注射液正式获得NMPA批准上市。正是基于这一科学假说，恒瑞医药启动了瑞拉芙普α注射液的研发项目。这一观点，与恒瑞医药董事、执行副总裁张连山博士在近期研发日上阐述的“平台驱动创新”战略不谋而合。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026013111482797a43dea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026013111482797a43dea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","BK1191","LU0359201885.HKD","LU1023057109.AUD","01276","LU0359202008.SGD","LU2543165471.USD"],"gpt_icon":0},{"id":"2607078996","title":"江苏恒瑞医药股份有限公司回购A股股份用于员工持股计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2607078996","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607078996?lang=zh_cn&edition=full","pubTime":"2026-01-31 09:12","pubTimestamp":1769821922,"startTime":"0","endTime":"0","summary":"中访网数据 江苏恒瑞医药股份有限公司于2026年1月30日披露了翌日披露报表，报告了其股份变动及回购情况。根据公告，公司于2026年1月30日通过上海证券交易所交易系统以集中竞价交易方式回购了343,100股A股股份，占公司总股本的约0.0054%。此次回购的每股最高价格为人民币58.21元，每股最低价格为人民币58.12元，支付的总金额为人民币19,959,865元。　　公告明确，本次回购的股份将全部用于公司A股员工持股计划。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260131/31989089.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU1328615791.USD","LU1655091616.SGD","LU1255011170.USD","LU2097828714.EUR","LU2097828805.USD","LU2495084118.USD","LU1580142542.USD","LU2097828631.EUR","LU0405327494.USD","LU2097828474.EUR","BK0183","600276","399300","BK0239","BK1191","LU1997245177.USD","LU2488822045.USD","LU1023057109.AUD","BK0060","LU2543165471.USD","LU2148510915.USD","LU2580892789.USD","LU0359201612.USD","LU1064131003.USD","159982","LU1969619763.USD","LU2289578879.USD","BK0196","LU0359202008.SGD","LU1146622755.USD","LU2328871848.SGD","BK0188","01276","LU1781817850.SGD","BK0012","LU1064130708.USD","LU0405327148.USD","LU1997244956.HKD","LU0359201885.HKD","LU1997245094.SGD","BK0028","LU2097828557.USD","LU1820825898.SGD","LU2580892862.HKD"],"gpt_icon":0},{"id":"2607073008","title":"Tides 周递 | 全球多肽和寡核苷酸药物一周要闻（1.22-1.30）","url":"https://stock-news.laohu8.com/highlight/detail?id=2607073008","media":"多肽圈","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607073008?lang=zh_cn&edition=full","pubTime":"2026-01-31 09:00","pubTimestamp":1769821223,"startTime":"0","endTime":"0","summary":"Brenipatide 是一款 GLP1R/GIPR 双激动剂，也是继替尔泊肽后，礼来第二款 GLP-1/GIP 双靶点新药。替尔泊肽 2025 年前三季度大卖了 248 亿美元，同比增长 125%。2023年12月，罗氏出手31亿美元收购Carmot Therapeutics，获得了该公司旗下的多款肠促胰岛素药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260131091614a6c20546&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260131091614a6c20546&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B543WZ88.USD","HK0000165453.HKD","IE0008368742.USD","LU1813983027.USD","LU1993786604.SGD","LU1226288253.USD","LU0072913022.USD","LU1951186391.HKD","LU0326950275.SGD","01276","IE00BZ08YR35.GBP","06938","LU0880133367.SGD","LU1152091168.USD","LU0315179316.USD","BK1191","LU0067412154.USD","LU1226287875.USD","IE00B031HY20.USD","01093","LU1008478684.HKD","LU1328277881.USD","LU0501845795.SGD","BK1521","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","IE0008369823.USD","LU0140636845.USD","LU1226287529.USD","LU1807302812.USD","LU1152091754.HKD","LU0314109678.HKD","LU2039709279.SGD","BK1515","SG9999004220.SGD","IE00BZ08YT58.USD","LU1960683339.HKD","LU1226288170.HKD","LU1226287792.SGD"],"gpt_icon":0},{"id":"2607142870","title":"恒瑞医药(01276)：注射用磷罗拉匹坦帕洛诺司琼(HR20013)的药品上市许可申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2607142870","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607142870?lang=zh_cn&edition=full","pubTime":"2026-01-30 19:18","pubTimestamp":1769771932,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 公布，近日，公司子公司福建盛迪医药有限公司收到国家药品监督管理局下发的《受理通知书》，公司注射用磷罗拉匹坦帕洛诺司琼的药品上市许可申请获国家药监局受理。此次申报新适应症，是基于一项评价注射用磷罗拉匹坦帕洛诺司琼用于预防中度致吐性抗肿瘤药物引起恶心呕吐的有效性和安全性的多中心、随机、双盲、阳性对照的Ⅲ期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0060","BK0196","LU0359201612.USD","LU1997244956.HKD","BK0183","LU2580892862.HKD","01276","LU2495084118.USD","600276","LU0405327148.USD","LU1064130708.USD","LU1655091616.SGD","LU1969619763.USD","LU1328615791.USD","LU0359201885.HKD","BK0188","LU2097828557.USD","LU1820825898.SGD","LU1997245177.USD","LU2580892789.USD","LU1997245094.SGD","LU1064131003.USD","LU2097828714.EUR","LU1146622755.USD","BK0012","LU0405327494.USD","LU2097828631.EUR","LU2488822045.USD","LU1023057109.AUD","LU2097828805.USD","LU2543165471.USD","BK1191","LU2289578879.USD","LU1781817850.SGD","LU1580142542.USD","LU2148510915.USD","BK0028","LU0359202008.SGD","LU1255011170.USD","LU2328871848.SGD","LU2097828474.EUR"],"gpt_icon":0},{"id":"2607793710","title":"恒瑞医药注射用SHR-A2102启动III期临床 适应症为局部晚期或转移性尿路上皮癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2607793710","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607793710?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:31","pubTimestamp":1769769060,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，苏州盛迪亚生物医药有限公司/上海恒瑞医药有限公司的注射用SHR-A2102联合阿得贝利单抗对比吉西他滨联合顺铂或卡铂一线治疗局部晚期或转移性尿路上皮癌的随机、开放、多中心III期临床研究已启动。注射用SHR-A2102为生物制品，适应症为局部晚期或转移性尿路上皮癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130183447a6bfd446&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130183447a6bfd446&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU0359202008.SGD","BK1191","LU1023057109.AUD","01276","LU2543165471.USD","LU0359201885.HKD"],"gpt_icon":0},{"id":"1186632406","title":"江苏恒瑞医药（600276）回购约34.31万股A股，涉及金额约1,996万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186632406","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186632406?lang=zh_cn&edition=full","pubTime":"2026-01-30 16:22","pubTimestamp":1769761346,"startTime":"0","endTime":"0","summary":"江苏恒瑞医药股份有限公司（600276）于2026年1月30日发布翌日披露报表，公告显示公司回购A股343,100股，用于A股员工持股计划，上述数量约占回购前已发行股份（不含库存股）总数的0.0054%。本次回购价格区间介于每股人民币58.12元至58.21元，累计支付金额约人民币1,995.99万元。\n回购完成后，公司已发行股份总数仍为6,379,002,274股，包括不含库存股的6,374,373,624股及库存股4,628,650股。公司在公告中表示，本次回购行为已获董事会正式授权，并遵循相关上市规则、法律及监管规定。\n本公告由联席公司秘书刘笑含签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"gpt_icon":0},{"id":"2607754110","title":"恒瑞医药新型口服小分子GLP-1受体激动剂HRS-7535用于高血压合并超重或肥胖获批Ⅲ期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2607754110","media":"恒瑞医药官网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607754110?lang=zh_cn&edition=full","pubTime":"2026-01-30 14:03","pubTimestamp":1769753004,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药子公司山东盛迪医药有限公司收到国家药品监督管理局核准签发的《药品临床试验批准通知书》，同意公司自主研发的1类创新口服小分子GLP-1受体激动剂HRS-7535片开展用于高血压合并超重或肥胖适应症的Ⅲ期临床研究。目前，全球范围内尚无口服小分子GLP-1R激动剂上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130140324a467be14&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130140324a467be14&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU0359201612.USD","LU1023057109.AUD","LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD","01276"],"gpt_icon":0},{"id":"2607507541","title":"江宁军：从中国走向全球，是恒瑞的必然路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2607507541","media":"恒瑞医药官微","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607507541?lang=zh_cn&edition=full","pubTime":"2026-01-30 13:24","pubTimestamp":1769750682,"startTime":"0","endTime":"0","summary":"恒瑞是中国本土药企中规模最大、也最具代表性的企业，正清晰描绘自身向大型跨国制药公司的转型路径。如今，恒瑞拥有超过100个在研项目，分布在400多项临床试验中。恒瑞采取多管齐下的策略推动海外拓展。江宁军表示，Kailera及GSK模式不仅帮助恒瑞将资产推向海外，也为公司带来了“非常宝贵的学习经验”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130133555a467a902&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130133555a467a902&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU0359201885.HKD","LU0359202008.SGD","LU0359201612.USD","LU2543165471.USD","LU1023057109.AUD","01276"],"gpt_icon":1},{"id":"2607025472","title":"AI重塑医药生产力，为何超六成医药企业拥抱钉钉？","url":"https://stock-news.laohu8.com/highlight/detail?id=2607025472","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607025472?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:43","pubTimestamp":1769737380,"startTime":"0","endTime":"0","summary":"以“AI重塑医药生产力”为主题的2026医药钉峰会日前在沪召开，共探人工智能技术如何驱动赋能医药行业。AI自动完成数据抓取、分析与预警，让人人皆可成为开发者，大幅提升了业务响应的敏捷性。此外，AI正成为药企全球化协同的基石。AI不再是遥远的技术概念，而是已经成为医药行业提质、增效、创新的核心驱动要素。随着AI技术产品持续完善、行业生态日益繁荣，一场以人工智能为核心的医药生产力革命，正从蓝图加速照进现实。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130095032a466dcda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260130095032a466dcda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1366334651.USD","LU0348788117.USD","LU0456846285.SGD","89988","LU1048588211.SGD","LU0708995153.HKD","LU0700851271.USD","LU0254981946.USD","LU1794554557.SGD","LU0328353924.USD","BK1142","LU0499858602.USD","LU1515016050.SGD","LU0577902371.SGD","LU1044876610.USD","LU0164880469.USD","LU0791590937.USD","BK1161","LU0327786744.USD","LU1568876335.HKD","LU0127658192.USD","LU0455707207.USD","SG9999002828.SGD","LU1282649810.SGD","LU0261947096.USD","LU1282649141.HKD","LU0449509016.USD","SG9999001093.SGD","LU0605514214.HKD","LU1770036033.HKD","LU0264606111.USD","LU1323998911.USD","LU0594300179.USD","BK1615","LU0128522157.USD","LU0214875030.USD","LU1328277881.USD","LU0784639295.USD","LU0106959298.USD","LU1366334578.USD","LU1720051108.HKD","LU2097828474.EUR","SG9999000327.SGD","LU1188198961.HKD","LU0898667661.SGD","LU0326950275.SGD","LU0348783662.USD","LU0543330483.HKD","IE00B3M56506.USD","BK1588","BK1618","HK0000320223.HKD","SG9999001051.SGD","LU0348783233.USD","LU0417516571.SGD","LU0048597586.USD","LU2152927971.USD","LU1961090484.USD","LU0251144936.SGD","LU0417516902.SGD","LU2257852520.SGD","LU2449936058.SGD","LU0261950983.USD","BK1586","SG9999002463.SGD","SG9999014674.SGD","HK0000306685.HKD","LU1719994722.HKD","BK1608","IE00BZ08YS42.EUR","LU1769817179.HKD","LU0314109678.HKD","LU0588545490.SGD","LU1242518857.USD","LU0117841782.USD","LU0823040885.USD","LU1251922891.USD","LU2125910849.SGD","LU1568876251.USD","LU0640798160.USD","LU0011963245.USD","LU0307460666.USD","LU0708995583.HKD","02607","IE0008368304.USD","IE00B5MMRT66.SGD","BK1517","LU0890818403.SGD","LU0228367735.SGD","LU0819121731.USD","LU1769817096.USD","BK1521","LU1224444064.USD","LU0531970944.HKD","LU0762542818.HKD","LU0370786039.SGD","LU0979878070.USD","LU2242644610.SGD","LU1807302812.USD","06127","LU1211504680.USD","000538","LU0871576103.HKD","LU0862451753.SGD","LU0594300419.USD","LU0572940350.SGD","LU0516423174.USD","LU0130103400.USD","LU0675040207.SGD","LU0577902538.SGD","LU1316542783.SGD","LU0611395673.USD","LU0132412106.USD","LU0672654166.SGD","LU0348825331.USD","LU0047713382.USD","LU1048484197.HKD","LU1808992512.USD","LU0862451837.USD","LU0210527791.USD","LU0823426308.USD","LU0287142896.SGD","LU1504937902.USD","LU1831875114.USD","LU0516423091.SGD","SG9999001226.SGD","LU1956131251.USD","LU0737861699.HKD","LU1201861165.SGD","LU0197773160.USD","LU0096374516.USD","600276","LU0762541174.USD","IE00BMPRXR70.SGD","LU1770034418.SGD","BK1249","LU2045819591.USD","LU1224709979.USD","LU1868837565.USD","LU0642271901.SGD","SG9999006514.SGD","LU0823413660.USD","LU0106252389.USD","LU0572944931.SGD","LU0828237510.HKD","LU0651947912.USD","LU0048580855.USD","LU0831103253.SGD","LU1981816686.USD","LU0868486357.SGD","LU0831093199.SGD","LU0572939691.SGD","LU0384037296.USD","BK1584","LU0823397285.USD","LU1720051017.SGD","SG9999000459.SGD","LU0164865239.USD","LU0456827905.SGD","LU1044875133.USD","LU1328615791.USD","LU0608807433.USD","LU1548497426.USD","603127","LU0052750758.USD","LU0329678337.USD","LU0823039010.USD","01801","LU1880383440.USD","LU0762540952.USD","LU0396098781.USD","LU0072462343.USD","LU0531971595.HKD","IE00B543WZ88.USD","LU0417516738.SGD","LU0607220059.USD","LU0043850808.USD","SG9999004220.SGD","BK1583","LU0431992006.USD","IE00BMPRXN33.USD","LU1810669033.SGD","LU0348784397.USD","BK1574","LU0149534421.HKD","LU1023057109.AUD","BK1610","LU0210526637.USD","LU0463099449.HKD","LU0488056044.USD","LU1969619763.USD","LU0348735423.USD","LU0737861772.HKD","LU0477156797.USD","BK1515","SHPMY","LU0821914370.USD","LU0516422440.USD","09988","LU0516422952.EUR","IE00BPRC5H50.USD","LU0211977185.USD","LU1242518931.SGD","IE00B0169N27.USD","LU0823038988.USD","LU0819123356.HKD","LU0593848301.USD","LU0865486749.SGD","LU0441854154.USD","LU0169518387.USD","LU2097828805.USD","LU0315179316.USD","LU0049853897.USD","LU0228659784.USD","LU1048596156.SGD","02157","LU0039217434.USD","LU0320764755.SGD","HK0000320264.USD","LU1868838027.USD","LU0029874905.USD","LU0499858438.USD","LU0791591158.USD","LU2087589342.USD","LU0588545904.SGD","LU0164872284.USD","SG9999001689.USD","IE00B0JY6N72.USD","IE0032431581.USD","LU0588546209.SGD","LU2357305700.SGD","SG9999002562.SGD","LU0856984785.SGD","LU0048388663.USD","LU0540923850.HKD","LU1993786604.SGD","LU2399975544.HKD","LU0128522744.USD","LU0165289439.USD","HK0000306701.USD","LU1044874839.SGD","LU0577902454.USD","LU0140636845.USD","LU1303224171.USD","LU0320764599.SGD","LU1282649067.USD","LU0084288322.USD","LU2293587155.HKD","LU0823397103.USD","LU0634319403.HKD","LU1688375341.USD","LU0886674414.USD","LU1282651121.HKD","LU2488822045.USD","LU0823413587.USD","LU0315178854.USD","LU0588545730.USD","LU0231483743.USD","LU0516422366.SGD","LU0244354667.USD","LU1813983027.USD","LU0648948544.HKD","LU1720050803.USD","LU2097828631.EUR","LU2476274308.USD","LU0359201612.USD","LU0181495838.USD","BK1591","LU0577902611.USD","LU0502904849.HKD","LU1880398554.USD","LU3063872942.SGD","LU0143863198.USD","LU1642822792.SGD","LU1439103000.SGD","LU1051768304.USD","LU0173614495.USD","LU2476274720.SGD","LU0469268626.HKD","LU0541502299.USD","BK1501","LU0106259558.USD","LU0293314216.USD","LU0029875118.USD","LU0828237940.HKD","601607","LU0648000940.SGD","LU0235996351.USD","01276","LU0359202008.SGD","HK0000165453.HKD","LU0061477393.USD","LU0630378429.USD","LU1196710864.SGD","IE00BZ08YR35.GBP","LU0051755006.USD","LU0130518102.USD","LU0149721374.USD","LU0608807946.USD","LU0054237671.USD","LU0348827113.USD","LU0543330566.HKD","LU1655091459.SGD","LU0359201885.HKD","LU0329678170.USD","LU0259732245.USD","LU2097829019.USD","BK1589","LU0196878994.USD","LU0561508036.HKD","SG9999006597.SGD","LU2328871848.SGD","LU2097828714.EUR","BK1502","LU0117844026.USD","IE0003895053.USD","LU2097828557.USD","LU1115378108.SGD","IE0034224299.USD","LU0229945570.USD","LU2778985437.USD","LU0320764243.SGD","LU0651946864.USD","BK1575","LU0143863784.USD","LU1880398471.USD","LU1880383366.USD","LU1960683339.HKD","LU2039709279.SGD","LU2125910500.SGD","LU0345775950.USD","SGXZ90724238.SGD","LU0589944569.HKD","LU0650527681.SGD","LU0197773673.USD","LU0449515922.USD","LU1282651048.USD","BABA","LU0873338254.USD","LU0823426480.USD","LU0823041008.USD","LU1051769294.HKD","ALBmain","LU1481107354.HKD","IE00BZ08YT58.USD","LU0163747925.USD","HBBD.SI","LU0630378692.HKD","LU0348805143.USD","LU0345776255.USD","LU0577902298.EUR","LU0541501648.USD","LU0054450605.USD","SG9999001903.USD"],"gpt_icon":1},{"id":"2607057702","title":"恒瑞医药(01276)获得HRS-7535片临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2607057702","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607057702?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:20","pubTimestamp":1769678459,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司子公司山东盛迪医药有限公司收到国家药品监督管理局核准签发关于 HRS-7535 片的《药物临床试验批准通知书》，将于近期开展临床试验。临床前数据显示 HRS-7535 可显著改善动物慢性肾脏病症状。全球范围内尚无口服小分子 GLP-1R 激动剂上市。截至目前，HRS-7535 片相关项目累计研发投入约 36,940 万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","LU1064131003.USD","LU2580892789.USD","LU2097828805.USD","LU2148510915.USD","LU2328871848.SGD","LU1820825898.SGD","LU0405327494.USD","BK0239","LU1997245094.SGD","BK0012","LU0359202008.SGD","LU1255011170.USD","LU1781817850.SGD","LU0359201885.HKD","LU2488822045.USD","01276","LU1997245177.USD","LU1146622755.USD","LU2097828631.EUR","LU2097828714.EUR","BK1191","LU1997244956.HKD","LU0405327148.USD","LU2495084118.USD","LU1969619763.USD","LU2097828474.EUR","LU1655091616.SGD","LU2289578879.USD","BK0028","LU2580892862.HKD","600276","LU2543165471.USD","LU2097828557.USD","LU1328615791.USD","BK0060","BK0196","LU1064130708.USD","BK0188","LU1580142542.USD","LU0359201612.USD","LU1023057109.AUD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.0389},{"period":"1month","weight":-0.1112},{"period":"3month","weight":-0.0787},{"period":"6month","weight":-0.1297},{"period":"1year","weight":0.5153},{"period":"ytd","weight":-0.0632}],"compareEarnings":[{"period":"1week","weight":-0.0352},{"period":"1month","weight":0.019},{"period":"3month","weight":0.0136},{"period":"6month","weight":0.08},{"period":"1year","weight":0.2914},{"period":"ytd","weight":0.0475}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}